Figure 4
Effect of NVP-BEZ235, a dual PI3K/mTOR inhibitor, on COX-2 and mPGES-1 immunoreactivity and PGE 2 and PGD 2 release in primary LPS-stimulated rat microglia. A: Immunoblot analysis of protein levels of COX-2, mPGES-1 and β-actin in LPS-activated microglia treated with NVP-BEZ235 (10-500 nM). B: Quantitative densitometric analysis of COX-2 and mPGES-1 protein expression normalized to β-actin loading control. C: Effect of NVP-BEZ235 (10-500 nM) on PGE2 and PGD2 production after 48 h of LPS stimulation in rat primary microglia. D: Effect of incubation of rat microglia with NVP-BEZ235 (10-500 nM) on COX-2 and mPGES-1 in absence of LPS. E: Quantitative densitometric analysis of COX-2 and mPGES-1 protein expression normalized to β-actin loading control. For COX-2, there is a trend toward statistical significance (P = 0.0675). F: Effect of incubation of rat microglia with NVP-BEZ235 (10-500 nM) on PGE2 release in absence of LPS. G: Effect of PI3K inhibitors (LY294002 and PI828), LY303511 (inactive analogue of PI3K inhibitor), rapamycin (mTOR inhibitor) and NVP-BEZ235 (PI3K/mTOR dual inhibitor) on p70S6K phosphorylation. *P < 0.05 with respect to LPS control.